2016
DOI: 10.4269/ajtmh.15-0477
|View full text |Cite
|
Sign up to set email alerts
|

A Unique Plasmodium falciparum K13 Gene Mutation in Northwest Ethiopia

Abstract: Abstract. Artemisinin combination therapy (ACT) is the first line to treat uncomplicated Plasmodium falciparum malaria worldwide. Artemisinin treatment failures are on the rise in southeast Asia. Delayed parasite clearance after ACT is associated with mutations of the P. falciparum kelch 13 gene. Patients (N = 148) in five districts of northwest Ethiopia were enrolled in a 28-day ACT trial. We identified a unique kelch 13 mutation (R622I) in 3/125 (2.4%) samples. The three isolates with R622I were from Negade-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

8
46
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 54 publications
(55 citation statements)
references
References 17 publications
8
46
1
Order By: Relevance
“…The absence of known mutations in the k13 propeller gene augurs favorably for the antimalarial efficacy of ACTs at least in the western part of Burkina Faso with high malaria transmission. Nevertheless, a recent study reported the identification of a unique K13 mutation from Ethiopia [4]. This R622I mutation is located on blade 5 of the K13 propeller domain and had not been seen in previous investigations in Africa.…”
Section: Discussionmentioning
confidence: 99%
“…The absence of known mutations in the k13 propeller gene augurs favorably for the antimalarial efficacy of ACTs at least in the western part of Burkina Faso with high malaria transmission. Nevertheless, a recent study reported the identification of a unique K13 mutation from Ethiopia [4]. This R622I mutation is located on blade 5 of the K13 propeller domain and had not been seen in previous investigations in Africa.…”
Section: Discussionmentioning
confidence: 99%
“…However, reports from Uganda and Equatorial Guinea have indicated the presence of resistant Pfk13 gene mutations in these countries (Pfk13 A675V and C580Y respectively) [45,46]. Another single mutation in the Pfk13 gene which might be associated with reduced clearance of parasites was reported from Ethiopia [47]. These reports are alarming for the malaria control programmes in Africa.…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, two years later, all parasites isolated from patients with treatment failure after AS-SP carried the quintuple mutation 51I/108N + 437G/540E/581G. The efficacy of AL was investigated in two studies in Ethiopia and Somalia (Bayih et al, 2016;Warsame et al, 2017). In the first study (Bayih et al, 2016), the association between AL clinical efficacy and the pfk13 mutation was found.…”
Section: Association Of Molecular Markers and Clinical Efficacymentioning
confidence: 99%
“…The recent emergence of P. falciparum ART resistance strains in Greater Mekong Sub-region (GMS) represents a challenge to the efficacy of ART and also will postpone the goal of malaria elimination by 2030 in the region (WHO, 2015). The dissemination of these strains to Africa, where the majority of deaths due to malaria occurs, will have catastrophic results (Bayih et al, 2016). Mutation of pfatp 6 (encodes P. falciparum SERCA-type ATPase 6) has initially been linked to resistance of P. falciparum to artemether (Heuchert et al, 2015).…”
Section: Introductionmentioning
confidence: 99%